Breaking News Headlines Today | Ground News

See every side of every news story

modernretina.com image

News from modernretina.com

See all of modernretina.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

In total, 150 have been published by modernretina.com which Ground News has aggregated in the past 3 months.

The Ground News media bias check for modernretina.com is unknown. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

modernretina.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about modernretina.com

Where is modernretina.com located?modernretina.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top modernretina.com News

Hims & Hers to Bring Generic Semaglutide to Canada

Health Canada · Canada

Hims & Hers to Bring Generic Semaglutide to Canada

49% Center coverage: 8 sources

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as Wegovy, will soon expire.See the Story

Nanoscope Begins Rolling Submission of Biologics License Application for RP Gene Therapy

United States · United States

Nanoscope Begins Rolling Submission of Biologics License Application for RP Gene Therapy

100% Center coverage: 2 sources

Nanoscope Therapeutics submitted the first modules of a biologics license application for MCO-010, an investigational gene therapy to treat severe vision loss in retinitis pigmentosa, to the FDA, according to a press release.See the Story

FDA fast-tracks Sanofi's gene therapy for eye disease GA

AMD · United States

FDA fast-tracks Sanofi's gene therapy for eye disease GA

100% Center coverage: 1 sources

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy, a major cause of blindness See the Story

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of ...

100% Center coverage: 1 sources

WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 30 -…San Francisco, California · San Francisco See the Story

Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy?

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.Read Article

Survey data show trends for AMD and DME treatments and future prospects

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements.AMD Read Article

Study links cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

A recent study reveals cannabis use may lower the risk of proliferative vitreoretinopathy after retinal detachment repair, suggesting potential therapeutic benefits.Read Article

Looming US Trade Tariffs Could Disrupt Optical Industry

New tariffs threaten the optical industry, prompting urgent reevaluation of sourcing strategies and pricing as deadlines approach.Tariffs · United States See the Story

FDA agrees to expand Atsena's gene therapy trial for XLRS treatment

Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.Read Article

CTO East Coast 2025: AI Can Speed Up All Parts Of Clinical Trial Ecosystem - Data Intelligence

Image credit: Thanos Psimidis / Arena International Artificial intelligence (AI) should soon be taking a greater role in areas including patient recruitment and in building efficiencies around data quality. That is the hope among those attending this year’s Clinical Trials in Oncology (CTO) East Coast 2025 conference, taking place on 8-9 July in Boston. During an interview with Clinical Trials Arena, Leena Gandhi, chief medical officer at NextPo…Artificial Intelligence · United States See the Story

A review of the DAVIO 2 phase 2 trial results

A hope for reducing treatment burden for wet age-related macular degeneration with a sustained-release vorolanib intravitreal insert Read Article

Breaking News Topics Related to modernretina.com